288 filings
Page 4 of 15
8-K
serjwgd nlw7enw
3 May 21
Intra-Cellular Therapies Announces FDA Acceptance of CAPLYTA® (lumateperone) sNDAs for the Treatment of Bipolar Depression
7:42am
DEFA14A
471xi21br2irzkmknfz
29 Apr 21
Additional proxy soliciting materials
5:09pm
DEFA14A
m9yg1py2fn7mxf0exg
20 Apr 21
Additional proxy soliciting materials
7:07am
PRE 14A
agz20onesg x8uk
19 Apr 21
Preliminary proxy
5:28pm
8-K
ys7 9ml9rx
25 Feb 21
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2020 Financial Results and Provides Corporate Update
7:54am
8-K
e6e660wft3thv7
22 Feb 21
Intra-Cellular Therapies Applies for FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression
8:09am
8-K
de5knyjfhm x4pnzkc6l
9 Nov 20
Intra-cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update
7:40am
8-K
br039dd00me
1 Oct 20
Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer
4:38pm
8-K
q9xl7scu4lfq08 3x
11 Sep 20
Entry into a Material Definitive Agreement
4:47pm
424B5
l1t5wb6sir5bov gc9jz
11 Sep 20
Prospectus supplement for primary offering
4:44pm
8-K
ica0sx yt9j
10 Sep 20
Termination of a Material Definitive Agreement
4:02pm
8-K
re5s bwdby339q3a
9 Sep 20
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
5:26pm
424B5
t8uqfrz716lch3l4re
9 Sep 20
Prospectus supplement for primary offering
4:40pm
8-K
z466 xfvvb59s
9 Sep 20
Intra-Cellular Therapies Announces Positive Topline Results
7:13am
S-8
6vp9e8
10 Aug 20
Registration of securities for employees
4:16pm
8-K
jn1nkyqok3 5cql61rhv
10 Aug 20
Intra-cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:52am